Company Encyclopedia
View More
name
Kiora Pharmaceuticals
KPRX.US
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders.
4.715 T
KPRX.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking163/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-32.58%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-253.92%E
    • Total Assets YoY-22.45%E
    • Net Assets YoY-25.37%E
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio24.96%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations

    Kiora Pharmaceuticals Inc. has been granted a new U.S. patent for novel formulations of its KIO-104 anti-inflammatory compound. The patent covers a non-steroidal, small molecule DHODH inhibitor, expanding delivery options and therapeutic utility. KIO-104 is in Phase 2 clinical trials for retinal inflammatory conditions. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    KPRX
    +1.57%
    Reuters·
    US
    KPRX
    +1.57%

    Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating

    Analyst Michael Okunewitch of Maxim Group has maintained a Buy rating on Kiora Pharmaceuticals with a price target of $12.00, citing the company's strong financial position and promising clinical developments. Despite a $2.5 million operating loss in Q3 2025, Kiora has a healthy cash reserve of $19.4 million, expected to fund operations into late 2027. The company is advancing two Phase 2 studies and has secured significant commercial agreements, enhancing its outlook.

    Tip Ranks·
    US
    KPRX
    +1.57%
    Tip Ranks·
    US
    KPRX
    +1.57%

    Earnings slated for Nov 7, 2025, with various companies like KPRX, DCBO, GYRE, RPID, GTN, ACRE, CTEV, AIRS, FLR & more expected to report.

    Earnings reports are scheduled for November 7, 2025, from various companies including Kiora Pharmaceuticals, Docebo, Gyre Therapeutics, and more. Kiora is expected to report a loss of $0.72 per share, while Docebo is projected to earn $0.32 per share. Gyre Therapeutics anticipates earnings of $0.01 per share. Other companies like Rapid Micro Biosystems, Gray Media, and Fluor are also expected to report losses or earnings, with Fluor projected to earn $0.45 per share on $4.17 billion revenue.

    Unusual Whales·
    US
    FLR
    -0.58%
    US
    DCBO
    +0.99%
    US
    KPRX
    +1.57%
    Unusual Whales·
    US
    FLR
    -0.58%
    US
    DCBO
    +0.99%
    US
    KPRX
    +1.57%

    Kiora Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    KPRX
    +1.57%
    LB filings·
    US
    KPRX
    +1.57%

    Kiora Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    KPRX
    +1.57%
    LB filings·
    US
    KPRX
    +1.57%
    © 2025 Longbridge｜Disclaimer